VistaGen Therapeutics(VTGN) - 2022 Q4 - Annual Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K VistaGen Therapeutics, Inc. (Exact name of registrant as specified in its charter) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Nevada 20-5093315 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) For the fiscal year ended: March 31, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Commis ...